Lexicon Pharmaceuticals Inc Stock Price and Quote (2024)

Held by: VTI IWM VXF SCHA IWN IWO VTWO BBP ITOT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.82	Insider Own	4.13%	Shs Outstand	361.49M	Perf Week	5.59%
Market Cap	614.53M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	0.00%	Shs Float	346.56M	Perf Month	3.03%
Income	-192.07M	PEG	-	EPS next Q	-0.18	Inst Own	46.60%	Short Float	6.72%	Perf Quarter	-31.45%
Sales	2.31M	P/S	266.03	EPS this Y	10.81%	Inst Trans	11.63%	Short Ratio	6.73	Perf Half Y	53.15%
Book/sh	1.17	P/B	1.45	EPS next Y	9.77%	ROA	-66.24%	Short Interest	23.27M	Perf Year	-48.48%
Cash/sh	0.98	P/C	1.73	EPS next 5Y	-	ROE	-101.92%	52W Range	0.92 - 3.73	Perf YTD	11.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.80%	ROI	-48.77%	52W High	-54.42%	Beta	1.38
Dividend TTM	-	Quick Ratio	15.56	Sales past 5Y	186.21%	Gross Margin	69.62%	52W Low	84.78%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	15.58	EPS Y/Y TTM	-30.42%	Oper. Margin	-8045.91%	RSI (14)	46.03	Volatility	4.25% 6.73%
Employees	285	Debt/Eq	0.37	Sales Y/Y TTM	1734.13%	Profit Margin	-8311.12%	Recom	1.80	Target Price	5.25
Option/Short	Yes / Yes	LT Debt/Eq	0.36	EPS Q/Q	-16.69%	Payout	-	Rel Volume	0.51	Prev Close	1.70
Sales Surprise	-21.43%	EPS Surprise	-11.11%	Sales Q/Q	4608.33%	Earnings	May 02 AMC	Avg Volume	3.46M	Price	1.70
SMA20	-3.41%	SMA50	-8.73%	SMA200	2.23%	Trades		Volume	1,760,781	Change	0.00%

open in yahoo|&nbspopen in reuters|&nbspopen in marketwatch|&nbspopen in google|&nbspopen in EDGAR

Lexicon Pharmaceuticals Inc Stock Price and Quote (1)

Lexicon Pharmaceuticals Inc Stock Price and Quote (2)

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	Leerink Partners	Outperform	$5
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26
Aug-05-16	Reiterated	Wedbush	Outperform	$30 → $31
Aug-02-16	Initiated	Citigroup	Buy	$21

Show Previous Ratings

Lexicon Pharmaceuticals Inc Stock Price and Quote (3)

May-30-24 04:45AM	Lexicon selects Medidata to advance Phase IIb non-opioid pain drug trial (Clinical Trials Arena)
May-29-24 07:30AM	Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024 (GlobeNewswire)
May-14-24 08:03AM	Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell (MT Newswires)
07:00AM	New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction (GlobeNewswire)
May-09-24 07:30AM	Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024 (GlobeNewswire) +6.78%
10:05AM	Loading…
May-06-24 10:05AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.17%
May-03-24 07:46AM	Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
04:07AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 08:59PM	LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:05PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:03PM	Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ... (GuruFocus.com)
05:00PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-24 10:42AM	Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire (MT Newswires)
09:00AM	Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals (GlobeNewswire)
07:00AM	Loading…
07:00AM	Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024 (GlobeNewswire)
Apr-18-24 08:00AM	Lexicon Pharmaceuticals to Host 2024 Investor Day (GlobeNewswire)
Apr-16-24 12:00PM	All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy (Zacks) -9.36%
Apr-03-24 08:00AM	Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.69%
Mar-25-24 09:20AM	Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo (GlobeNewswire) -6.19%
Mar-13-24 12:45PM	Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin (Zacks)
Mar-12-24 08:00AM	New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire) -10.32%
Mar-11-24 08:25AM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +29.49%
07:34AM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
07:15AM	Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:05AM	Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities (GlobeNewswire)
07:00AM	Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA (GlobeNewswire)
Feb-29-24 10:00AM	Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-22-24 12:58PM	15 Hot Penny Stocks On the Move (Insider Monkey) -5.58%
Jan-31-24 05:06AM	3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts (Motley Fool) +6.25%
05:21AM	Loading…
Jan-23-24 05:21AM	3 of the Fastest-Growing Stocks on the Planet in 2024 (Motley Fool) +15.94%
Jan-08-24 07:00AM	Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-23 05:06AM	3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street (Motley Fool) +7.63%
Dec-21-23 04:15PM	Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference (GlobeNewswire)
Nov-30-23 07:30AM	Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Nov-22-23 07:30AM	Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-15-23 01:03AM	Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc (GuruFocus.com)
Nov-12-23 02:10PM	INPEFA (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data (GlobeNewswire)
Nov-10-23 04:01PM	Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
10:53AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 09:45PM	Q3 2023 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.80%
07:19AM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 09:00AM	Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023 (GlobeNewswire) +5.71%
Nov-02-23 09:00AM	Data on Early Clinical Benefit for INPEFA (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023 (GlobeNewswire)
Nov-01-23 09:00AM	INPEFA (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients (GlobeNewswire) +8.06%
Oct-31-23 04:01PM	Lexicon Strengthens Management Team With Two New Executives (GlobeNewswire)
Oct-30-23 04:01PM	New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting (GlobeNewswire) +8.11%
Oct-25-23 08:45AM	Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027 (PR Newswire)
Oct-17-23 04:01PM	Data From Two Studies Demonstrating Positive Financial Impact of INPEFA (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting (GlobeNewswire) -8.09%
01:35PM	Hedge Fund and Insider Trading News: John Paulson, Ray Dalio, Starboard Value, Trian Fund Management, ExodusPoint Capital Management, JAT Capital, Lexicon Pharmaceuticals, Inc. (LXRX), Omnicom Group Inc. (OMC), and More (Insider Monkey)
Oct-13-23 11:38AM	Hedge Fund and Insider Trading News: Leon Cooperman, Ray Dalio, Bill Ackman, John Paulson, Altana Wealth Ltd., Apple Inc. (AAPL), Lexicon Pharmaceuticals Inc (LXRX), and More (Insider Monkey) +14.42%
Oct-11-23 11:13AM	Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts (Zacks)
09:00AM	Data Demonstrating Financial Impact of INPEFA (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting (GlobeNewswire)
Oct-10-23 11:25AM	Why Shares of Lexicon Pharmaceuticals Are Up Tuesday (Motley Fool) +12.00%
09:44AM	Midday movers: PepsiCo, Unity, Rivian Automotive and more (Investing.com)
03:33AM	Lexicon Pharma shares rise after Inpefa gets preferred status at Express Scripts (Investing.com)
Oct-09-23 04:01PM	INPEFA (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients (GlobeNewswire) -7.41%
08:00AM	Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer (GlobeNewswire)
Sep-28-23 09:00AM	Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 (GlobeNewswire) -9.09%
Sep-26-23 09:00AM	Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) (GlobeNewswire) +10.38%
Sep-20-23 12:28PM	15 Best Affordable Stocks To Buy Under $5 (Insider Monkey)
Sep-14-23 09:40PM	Insider Buying: Jeffrey Wade Acquires 10,000 Shares of Lexicon Pharmaceuticals Inc (LXRX) (GuruFocus.com)
Sep-07-23 04:30PM	Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference (GlobeNewswire)
09:00AM	Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Aug-21-23 09:00AM	Lexicon to Present Analyses of INPEFA (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023 (GlobeNewswire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-08-23 09:00AM	Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure (GlobeNewswire) +7.06%
Aug-04-23 09:12AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 49%, while individual investors hold 25% (Simply Wall St.)
Aug-03-23 05:15PM	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Lexicon: Q2 Earnings Snapshot (AP Finance)
04:01PM	Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-23 04:01PM	Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023 (GlobeNewswire)
08:00AM	Lexicon Elects Diane E. Sullivan to Board of Directors (GlobeNewswire)
Jun-30-23 06:52AM	Daily Vickers Top Buyers & Sellers for 06/30/2023 (Argus Research) +5.53%
Jun-27-23 06:46AM	Daily Vickers Top Buyers & Sellers for 06/27/2023 (Argus Research)
Jun-23-23 08:45PM	Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development (GlobeNewswire)
09:24AM	Daily Vickers Top Buyers & Sellers for 06/23/2023 (Argus Research)
Jun-20-23 08:00AM	Lexicon to Present Study Results Relating to LX9211 and INPEFA (Sotagliflozin) at the American Diabetes Associations 83rd Scientific Sessions (GlobeNewswire)
Jun-15-23 05:00PM	UPDATE: Lexicon Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure (GlobeNewswire)
Jun-06-23 04:01PM	Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference (GlobeNewswire)
Jun-05-23 04:01PM	Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares (GlobeNewswire) -7.47%
Jun-04-23 07:00AM	The Word Is, 'Lexicon' Is Worth a Trade (TheStreet.com)
Jun-02-23 09:21AM	Why Lexicon Pharmaceuticals Stock Crashed This Week (Motley Fool)
Jun-01-23 11:35AM	Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More (Zacks) -17.88%
08:00AM	Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
May-31-23 04:01PM	Lexicon Announces Proposed Public Offering of Common Stock (GlobeNewswire) +13.79%
May-26-23 04:25PM	UPDATE 2-U.S. FDA approves Lexicon Pharma's drug for heart failure (Reuters) +9.66%
04:08PM	U.S. FDA approves Lexicon Pharma's heart failure drug (Reuters)
04:05PM	Lexicon Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure (GlobeNewswire)
May-22-23 07:33AM	Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data (Investing.com) +6.64%
May-11-23 06:50AM	Wall Street's Counting on an FDA Nod for This Growth Stock to Nearly Double, but Should You? (Motley Fool)
May-10-23 04:30PM	New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure (GlobeNewswire)
May-04-23 10:05AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2023 Earnings Call Transcript (Insider Monkey) +12.41%
May-03-23 11:45AM	Q1 2023 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +15.13%
May-02-23 04:00PM	Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 04:00PM	Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023 (GlobeNewswire)
Apr-22-23 08:15AM	Should You Buy This Growth Stock Right Now Before It Potentially Doubles? (Motley Fool)
Apr-21-23 09:00AM	Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023 (GlobeNewswire)
Apr-17-23 04:00PM	Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +11.62%

Lexicon Pharmaceuticals Inc Stock Price and Quote (4)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Lexicon Pharmaceuticals Inc Stock Price and Quote (5)

Lexicon Pharmaceuticals Inc Stock Price and Quote (6)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SOBECKI CHRISTOPHER J	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	167,055	Apr 29 04:20 PM
Swain Judith L	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	48,364	Apr 29 04:21 PM
DEBBANE RAYMOND	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	1,348,879	Apr 29 04:17 PM
LEFKOWITZ ROBERT J MD	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	48,364	Apr 29 04:18 PM
BARKER SAM L	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	87,649	Apr 29 04:17 PM
Amouyal Philippe	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	248,364	Apr 29 04:16 PM
COATS LONNEL	Chief Executive Officer	Nov 16 '23	Buy	1.05	90,000	94,797	914,359	Nov 17 04:55 PM
COATS LONNEL	Chief Executive Officer	Nov 10 '23	Buy	1.01	10,000	10,100	824,359	Nov 13 05:31 PM
DEBBANE RAYMOND	Director	Oct 12 '23	Buy	1.03	148,820	153,805	1,340,847	Oct 12 04:01 PM
DEBBANE RAYMOND	Director	Oct 11 '23	Buy	1.08	342,874	370,784	1,192,027	Oct 12 04:01 PM
DEBBANE RAYMOND	Director	Oct 10 '23	Buy	1.14	508,306	579,367	849,153	Oct 12 04:01 PM
WADE JEFFREY L	President and CFO	Sep 14 '23	Buy	1.38	10,000	13,800	264,341	Sep 14 05:05 PM
McDermott Wendy	VP, Human Resources	Aug 04 '23	Buy	1.84	6,000	11,040	28,478	Aug 07 04:13 PM
COATS LONNEL	Chief Executive Officer	Jun 29 '23	Buy	2.16	10,000	21,600	814,359	Jun 29 04:13 PM
COATS LONNEL	Chief Executive Officer	Jun 26 '23	Buy	2.18	10,000	21,792	804,359	Jun 26 04:04 PM
COATS LONNEL	Chief Executive Officer	Jun 23 '23	Buy	2.50	10,000	24,950	794,359	Jun 26 04:04 PM
McDermott Wendy	VP, Human Resources	Jun 23 '23	Buy	2.43	10,000	24,300	22,478	Jun 27 04:22 PM
COATS LONNEL	Chief Executive Officer	Jun 22 '23	Buy	2.31	40,000	92,400	784,359	Jun 22 04:01 PM
WADE JEFFREY L	President and CFO	Jun 20 '23	Buy	2.33	12,000	28,000	254,341	Jun 20 04:10 PM
Artal International S.C.A.	Director	Jun 05 '23	Buy	2.60	27,775,050	72,215,130	78,634,381	Jun 05 04:46 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions withourpremium features. Real-time quotes, advancedvisualizations, backtesting, and much more.

Learn more about FINVIZ*Elite